Chimerix Inc (CMRX) Given Consensus Rating of “Hold” by Brokerages
Shares of Chimerix Inc (NASDAQ:CMRX) have been given an average rating of “Hold” by the six research firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, one has issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $8.00.
A number of research firms have recently commented on CMRX. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Chimerix in a research report on Friday, September 7th. Zacks Investment Research lowered shares of Chimerix from a “buy” rating to a “hold” rating in a research report on Tuesday, August 14th. Finally, ValuEngine raised shares of Chimerix from a “sell” rating to a “hold” rating in a research report on Friday, June 1st.
Large investors have recently added to or reduced their stakes in the company. MetLife Investment Advisors LLC bought a new position in shares of Chimerix in the first quarter valued at approximately $127,000. Wells Fargo & Company MN raised its position in shares of Chimerix by 46.1% in the first quarter. Wells Fargo & Company MN now owns 33,569 shares of the biopharmaceutical company’s stock valued at $175,000 after purchasing an additional 10,598 shares during the period. A.R.T. Advisors LLC bought a new position in shares of Chimerix in the first quarter valued at approximately $252,000. Acadian Asset Management LLC raised its position in shares of Chimerix by 63.3% in the second quarter. Acadian Asset Management LLC now owns 155,067 shares of the biopharmaceutical company’s stock valued at $738,000 after purchasing an additional 60,087 shares during the period. Finally, Spark Investment Management LLC bought a new position in shares of Chimerix in the second quarter valued at approximately $917,000. 72.98% of the stock is currently owned by institutional investors.
Chimerix (NASDAQ:CMRX) last issued its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.05. The firm had revenue of $1.19 million for the quarter, compared to analyst estimates of $0.94 million. Chimerix had a negative net margin of 1,582.64% and a negative return on equity of 34.94%. equities analysts expect that Chimerix will post -1.66 EPS for the current year.
Chimerix Company Profile
Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.
Featured Article: Why do earnings reports matter?
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.